TITLE

Brand-name drug companies fail to meet R&D commitments

AUTHOR(S)
Kondro, Wayne
PUB. DATE
August 2005
SOURCE
CMAJ: Canadian Medical Association Journal;8/15/2006, Vol. 175 Issue 4, p344
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This article focuses on a report released by the Patented Medicines Prices Review Board which indicated that spending on brand name drugs continues to increase while outlays for research and development remained lower in Canada. Drug sales increased by 1.3 percent to $16.1 billion. Bill C-22, which was implemented in 1987, provides new drugs protection from compulsory licensing for 7 to 10 years.
ACCESSION #
21988384

 

Related Articles

  • PRESCRIPTION DRUGS: INDIA VALUES THEIR COMPULSORY LICENSING PROVISION--SHOULD THE UNITED STATES FOLLOW IN INDIA'S FOOTSTEPS? Sands, Katharine W. // Houston Journal of International Law;Fall2006, Vol. 29 Issue 1, p191 

    The article examines the use of compulsory licensing of patents in the pharmaceutical industry in India and in what form it has been proposed in the U.S. The U.S. Congress have initiated efforts to combat the high cost of drugs such as the modification of drug discount plans and expansion of the...

  • What is compulsory licensing?  // Chemical Business;Dec2001, Vol. 15 Issue 12, p5 

    Focuses on compulsory licensing rules in the Indian pharmaceutical industry, which allows the government to ask drug manufacturers to produce patented drugs. Benefits to the pharmaceutical industry; Highlights of the World Trade Organization meeting on health considerations; Countries which...

  • Licença compulsória do efavirenz no Brasil em 2007: contextualização. Rodrigues, William C. V.; Soler, Orenzio // Revista Panamericana de Salud Publica;Dec2009, Vol. 26 Issue 6, p553 

    The article focuses on a study which contextualizes the first Brazilian experience with compulsory licensing for preventing excessive drug pricing by holders of patents. It notes that the government has the power to authorize a third party to explore a patented object in the absence of previous...

  • CHEAP DRUGS AT WHAT PRICE TO INNOVATION: DOES THE COMPULSORY LICENSING OF PHARMACEUTICALS HURT INNOVATION? Chien, Colleen // Berkeley Technology Law Journal;Summer2003, Vol. 18 Issue 3, p853 

    The patent system is built on the premise that patents provide an incentive for innovation by offering a limited monopoly to patentees. The inverse assumption that removing patent protection will hurt innovation has largely prevented the widespread use of compulsory licensing—the practice...

  • The link between publicly funded health care and compulsory licensing. Hollis, Aidan // CMAJ: Canadian Medical Association Journal;10/1/2002, Vol. 167 Issue 7, p765 

    Questions whether there is justification for compulsory licensing of pharmaceuticals and other medical services in the developed world. Idea that compulsory licensing involves breaking a patent right in order to change the terms of bargaining between a buyer and a seller; Standard analysis of...

  • Drugs withheld.  // New Scientist;3/24/2007, Vol. 193 Issue 2596, p7 

    The article states that the U.S. pharmaceutical company Abbott has decided to not sell seven drugs in Thailand. This decisions stems from Thailand issuing a compulsory license for Abbott's anti-human immunodeficiency virus (HIV) drug Kaletra. Drug companies typically oppose actions that undercut...

  • Price Differentiation and Transparency in the Global Pharmaceutical Marketplace. Ridley, David B. // PharmacoEconomics;2005, Vol. 23 Issue 7, p651 

    Pharmaceutical manufacturers have increased the availability of their products and sometimes increased their own financial returns by charging lower prices outside of the US and by discounting to lower-income patients in the US. Examples include discounted HIV-AIDS drugs in developing countries...

  • Cipla's New Battle. KARMALI, NAAZNEEN // Forbes Asia;Jul2012, Vol. 8 Issue 8, p22 

    An interview with Yusuf Hamied, chairman of Cipla Ltd. is presented. When asked about the decline in the prices of the drugs, he states that the mission of the company is to sell affordable drugs and contribute the health care. Hamied believes that India should adopt the compulsory licensing...

  • INDIAN SCENE.  // Chemical Business;Dec2001, Vol. 15 Issue 12, p43 

    Presents news briefs on the chemical and pharmaceutical industries in India as of December 2001. Concerns of the pharmaceutical industry regarding the compulsory licensing rule of the World Trade Organization; Expected growth in generic drugs export; Merger between CHEMB.Com and ChemXL;...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics